Find Clinical Trial

Efficacy and safety of agomelatine with flexible dose (25 mg/day with blinded potential adjustment at 50 mg) given orally for 8 weeks in Indian outpatients with Major Depressive Disorder A randomised double-blind national multicentric study with parallel groups, versus sertraline (50 mg/day with blinded potential adjustment at 100 mg).

← Back
Study Phase

Phase 3

Therapeutic Area

Neuropsychiatric Diseases

IndicationMajor Depressive Disorder
SponsorInstitut de Recherches Internationales Servier (I.R.I.S)
Active substance/
Medical device


Active Substance CodeS020098
Protocol CodeCL3-20098-074

Documents and links

Results summary READ MORE

Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.

© 2024 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.